**Supplementary Materials**

Supplementary Table S1. Baseline characteristics of patients in STAMP and STRIDE trials stratified by lower, middle, and upper tertiles of CTL activity

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **Antigen PAP** | **Antigen PA2024** |
| Lower Tertile(n=8) | Middle Tertile(n=7) | Upper Tertile(n=7) | Lower Tertile(n=8) | Middle Tertile(n=7) | Upper Tertile(n=7) |
| Median age, years (range)  | 75 (56-84) | 74 (60-91) | 68 (58-74) | 79 (56-91) | 72 (60-81) | 68 (58-79) |
| Race, n (%)CaucasianAfrican American | 8 (100)0 (0) | 6 (86)1 (14) | 7 (100)0 (0) | 8 (100)0 (0) | 7 (7)0 (0) | 6 (86)1 (14) |
| ECOG PS, (n%)01 | 8 (100)0 (0) | 5 (71)2 (29) | 6 (86)1 (14) | 7 (87)1 (13) | 7 (100)0 (0) | 5 (71)2 (29) |
| Gleason sum, n (%) ≤67≥8 | 0 (0)2 (25)6 (75) | 1 (14)2 (29)4 (57) | 1 (14)2 (29)4 (57) | 0 (0)2 (25)6 (75) | 1 (14)2 (29)4 (57) | 1 (14)2 (29)4 (57) |
| Median serum PSA, mg/mL (range) | 14.9 (0.6-85.8) | 8.4 (2.3-135.2) | 22.7 (2.4-144.7) | 34.4 (4.3-85.8) | 5.0 (0.6-60.0) | 22.7 (2.4-144.7) |
| Median LDH, U/L (range) | 180.0 (106.0-231.0) | 192.0 (123.0-237.0) | 194.0 (146.0-207.0) | 173.5 (123.0-231.0) | 194.0 (106.0-237.0) | 183.0 (146.0-207.0) |
| Median alkaline phosphatase, U/L (range) | 93.0 (50.0-161.0) | 80.0 (71.0-121.0) | 87.0 (67.0-130.0) | 84.0 (50.0-151.0) | 80.0 (72.0-161.0) | 87.0 (67.0-130.0) |
| Albumin, g/dL (range)  | 3.9 (3.4-4.1) | 4.0 (3.7-4.3) | 4.1 (3.9-4.7) | 4.0 (3.4-4.3) | 3.8 (3.7-4.4) | 4.1 (3.9-4.7) |
| Median time from diagnosis to randomization, years | 2.1 (1.0-21.4) | 8.2 (0.9-22.2) | 2.9 (1.2-15.7) | 2.0 (1.0-13.5) | 2.3 (0.9-22.2) | 5.5 (1.2-15.7) |

ECOG PS = Eastern Cooperative Oncology Group performance status; LDH = lactate dehydrogenase; PSA = prostate-specific antigen.